Posted by admin on May 6, 2009 | No Comments
Tuesday, May 5, 2009 – 3:10 PM
Fortress Investments
So today I took a dip into FIG, Fortress Investment Group. Admittedly I’m a bit later than I want to be, but this thing is moving ridiculously fast. Tomorrow, Fortress has it’s earnings call so we’ll have a lot more information on how it’s doing.
So the thesis on Fortress would be this: if you believe the worst is over, and that Fortress can make money buying assets at a discount, they they should do very well over the next few years, and even the next year.
The stock got hammered because it was a private equity play, and we all know what happened there. It was as low as the $2 range because in january, significant redemptions lowered their assets under management. Mark to market hit their books, and some of their companies had debt problems.
To believe fortress will do well, you have to look favorably on these factors:
1) the redemptions have stopped because the market is no longer staring at a downward spiral.
2) the companies that they’ve invested in have debt situations that are manageable. We’ll get more info on this tomorrow, but in their last earnings call, they said they’ve taken care of a lot of it.
3) they will be participants in the TALF, meaning they will be buying assets with government backing for a heavy discount. If we assume they’re pretty smart guys, they should come out making a profit. Regardless of what happens with the stress tests, these guys should be busy buying assets at a discount.
Fortress is a bit on the speculative side at the moment. Truth be told, earnings tomorrow is a toss up. They could beat, or there could be problems we don’t know about. The argument for beating is that a lot of the market has beat, and similar firm Blackrock is doing really well; the downside is that some other asset managers, like Legg Mason, reported today and didn’t do as well as expected. Still at $6-7, I don’t mind nibbling at FIG and being speculative.
Looking Past the Stress Tests
I still can’t tell you which way the market will go with the stress tests. Everything could be priced in, the market could use it as an excuse to take profits, or the sideline money could come in. In other words, I can’t tell. I’m inclined to think that there won’t be any huge sell off because we know that the stress tests will be positive, and recent buyers won’t have a reason to sell.
So I’m looking past the stress tests, and the only trade I see is being in the survivors, and especially those that will repay the TARP first. That puts Goldman and JP Morgan in front. Goldman, as I’ve said, I definitely like going into the stress tests. I can’t see how they’d come out badly, and the worst case I can see is profit taking. JP Morgan should do well also, and both are in discussions to repay TARP. Jaime Dimon has said discussions will start as soon as the stress test results are released. Morgan Stanley hasn’t said much about paying back the TARP, but there’s been no sign that they need to raise capital, and their fundamentals are fine, other than commercial real estate on their books. Also, Morgan Stanley has broken resistance at $26. On dips, I like all three, but in order, Goldman, JP Morgan, Morgan Stanley. Of couse, I’m watching Wells, BAC, C and USB carefully. I have positions in all except Wells.
There may also be a play in Bank of America if a conversion does not occur. Currently, the possibility of government conversion of preferred is priced in, at least in part, I would argue. If that doesn’t happen, BAC should move.
Mastercard
A few days ago, Mastercard was down as much as $13, from $183 because it lowered full year estimates. Today, it’s back at $183, which tells you how much the market likes mastercard. Put it on your radar screens, buy on any dip. I bought a little at $170, thinking I’d buy a little more if it went down more. Well, it didn’t.
Playing the Secondary Offering
We all know that there will be banks, and other firms raising money over the next several months. For the last year, there has been a play in secondaries. The most familiar case might be Goldman; it raised money at $123 or so around earnings time. For a moment, it drifted down to $120 or so before the secondary, and down to $115 after the secondary. Since then it’s climbed to $135 today. So the simple play is this: the secondary stock offering will drive the price of the stock down because of dilution. Usually, it’s occurred within a day or two of the announcement. The trade is to buy going into, or just after the secondary, because the stock recovers. You can only do this if the successful secondary stock offering is a sign of strength. Meaning that the company isn’t raising money out of weakness. Recently, Northern Trust (NTRS) and US Steel (X) has done the same, and both have a seen a quick rise in the stock after the secondary. Dow Chemical (DOW) just announced a secondary today, I wouldn’t trade that one because it’s coming out of weakness, not strength.
I am long FIG, GS, MS, JPM, C, USB, MA, . Those are my thoughts for the day,
ming